TAKEDA PHARMACEUTICAL CO LTD files 6-K

Takeda Pharmaceutical Company Limited reported a net loss of JPY 152.1 billion for the fiscal year ended March 31, 2026, compared to a net profit of JPY 108.1 billion in the prior fiscal year, primarily due to a JPY 403.5 billion provision for legal proceedings related to the AMITIZA antitrust litigation. Despite this, the company projects a net profit attributable to owners of the Company of JPY 166.0 billion for the fiscal year ending March 31, 2027.